Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 26, Issue 9, Pages 1033-1048
Publisher
Informa UK Limited
Online
2017-08-04
DOI
10.1080/13543784.2017.1364360
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study
- (2017) Shu-Yu Tai et al. Neurotherapeutics
- Comparison of the Pharmacological Profiles of Selective PDE4B and PDE4D Inhibitors in the Central Nervous System
- (2017) Chong Zhang et al. Scientific Reports
- Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer’s disease
- (2017) Roberta Ricciarelli et al. Scientific Reports
- The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses
- (2016) Tim Vanmierlo et al. BEHAVIOURAL BRAIN RESEARCH
- First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males
- (2016) Viktoria Moschetti et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Adamantane – A Lead Structure for Drugs in Clinical Practice
- (2016) Katarina Spilovska et al. CURRENT MEDICINAL CHEMISTRY
- Cross-regulation of Phosphodiesterase 1 and Phosphodiesterase 2 Activities Controls Dopamine-mediated Striatal α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Trafficking
- (2016) Roy S. Song et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases
- (2016) Peng Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phosphodiesterase 11A (PDE11A), Enriched in Ventral Hippocampus Neurons, is Required for Consolidation of Social but not Nonsocial Memories in Mice
- (2016) Shweta Hegde et al. NEUROPSYCHOPHARMACOLOGY
- PDE11A regulates social behaviors and is a key mechanism by which social experience sculpts the brain
- (2016) Shweta Hegde et al. NEUROSCIENCE
- Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats
- (2016) Gretchen L. Snyder et al. PSYCHOPHARMACOLOGY
- Approved drugs are to be studied for use in Alzheimer’s disease
- (2016) Janice Hopkins Tanne BMJ-British Medical Journal
- Approved drugs are to be studied for use in Alzheimer’s disease
- (2016) Janice Hopkins Tanne BMJ-British Medical Journal
- The object pattern separation (OPS) task: A behavioral paradigm derived from the object recognition task
- (2015) B.T.J. van Hagen et al. BEHAVIOURAL BRAIN RESEARCH
- Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling
- (2015) Natura Myeku et al. NATURE MEDICINE
- Decreased levels of guanosine 3′, 5′-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease
- (2015) Ana Ugarte et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer’s Disease
- (2014) Elias Schwam et al. Current Alzheimer Research
- Phosphodiesterase Inhibitors as a Target for Cognition Enhancement in Aging and Alzheimer’s Disease: A Translational Overview
- (2014) P.R.A. Heckman et al. CURRENT PHARMACEUTICAL DESIGN
- cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases
- (2014) Ana Martinez et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Post-study caffeine administration enhances memory consolidation in humans
- (2014) Daniel Borota et al. NATURE NEUROSCIENCE
- PDE4D inhibitors: A potential strategy for the treatment of memory impairment?
- (2014) Olga Bruno et al. NEUROPHARMACOLOGY
- Improved Long-Term Memory via Enhancing cGMP-PKG Signaling Requires cAMP-PKA Signaling
- (2014) Eva Bollen et al. NEUROPSYCHOPHARMACOLOGY
- Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer’s Disease
- (2014) Mark E. Gurney et al. Neurotherapeutics
- Cilostazol Add-On Therapy in Patients with Mild Dementia Receiving Donepezil: A Retrospective Study
- (2014) Masafumi Ihara et al. PLoS One
- Performance on a pattern separation task by Alzheimer’s patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ∈4 status and cerebrospinal fluid amyloid-β42 levels
- (2014) Keith A Wesnes et al. Alzheimers Research & Therapy
- The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma
- (2014) Brian R Leaker et al. BMC Pulmonary Medicine
- Translational Issues with the Development of Cognition Enhancing Drugs
- (2014) Arjan Blokland et al. Frontiers in Neurology
- Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice
- (2013) Junfang Zhang et al. BEHAVIOURAL BRAIN RESEARCH
- PDE2 inhibition: Potential for the treatment of cognitive disorders
- (2013) Laurent Gomez et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Structural basis for the design of selective phosphodiesterase 4B inhibitors
- (2013) David Fox et al. CELLULAR SIGNALLING
- PDE4 as a target for cognition enhancement
- (2013) Wito Richter et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Spatial discrimination deficits as a function of mnemonic interference in aged adults with and without memory impairment
- (2013) Zachariah M. Reagh et al. HIPPOCAMPUS
- Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study
- (2013) Y S Shim et al. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH
- The effects of the phosphodiesterase type 5 inhibitor vardenafil on cognitive performance in healthy adults: a behavioral- electroencephalography study
- (2013) OAH Reneerkens et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease
- (2013) Rocio Perez-Gonzalez et al. NEUROBIOLOGY OF AGING
- Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D
- (2013) A.S.R. Sierksma et al. NEUROPHARMACOLOGY
- Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis
- (2013) Akihiko Taguchi et al. Psychogeriatrics
- Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801
- (2012) Olga A.H. Reneerkens et al. BEHAVIOURAL BRAIN RESEARCH
- Identification of Biologically Active PDE11-Selective Inhibitors Using a Yeast-Based High-Throughput Screen
- (2012) Ozge Ceyhan et al. CHEMISTRY & BIOLOGY
- PDE Inhibition and cognition enhancement
- (2012) Arjan Blokland et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Inactivation of Pde8b enhances memory, motor performance, and protects against age-induced motor coordination decay
- (2012) L.-C. L. Tsai et al. GENES BRAIN AND BEHAVIOR
- Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: A pilot study
- (2012) Hirofumi Sakurai et al. Geriatrics & Gerontology International
- Phosphodiesterases in neurodegenerative disorders
- (2012) Eva Bollen et al. IUBMB LIFE
- Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease
- (2012) Annerieke S.R. Sierksma et al. NEUROPHARMACOLOGY
- Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD
- (2012) Carolina García-Barroso et al. NEUROPHARMACOLOGY
- The PDE5 inhibitor vardenafil does not affect auditory sensory gating in rats and humans
- (2012) O. A. H. Reneerkens et al. PSYCHOPHARMACOLOGY
- Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation
- (2011) Sun Haeng Park et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- 1,5-Substituted nipecotic amides: Selective PDE8 inhibitors displaying diastereomer-dependent microsomal stability
- (2011) Michael P. DeNinno et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses
- (2011) O Bruno et al. BRITISH JOURNAL OF PHARMACOLOGY
- Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's disease
- (2011) M Cuadrado-Tejedor et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments
- (2011) Thérèse Keravis et al. BRITISH JOURNAL OF PHARMACOLOGY
- PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia
- (2011) Jan Kehler et al. CURRENT PHARMACEUTICAL DESIGN
- Effects of Add-On Cilostazol on Cognition in Patients With Schizophrenia
- (2011) Yukihiko Shirayama et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents
- (2011) P.H. Hutson et al. NEUROPHARMACOLOGY
- Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats
- (2011) Joshua S. Rodefer et al. NEUROPHARMACOLOGY
- Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment
- (2010) Michel Gallant et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Cilostazol prevents amyloid β peptide25-35-induced memory impairment and oxidative stress in mice
- (2010) Masayuki Hiramatsu et al. BRITISH JOURNAL OF PHARMACOLOGY
- Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues
- (2010) Viktor Lakics et al. NEUROPHARMACOLOGY
- The preclinical pharmacology of roflumilast – A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease
- (2010) Armin Hatzelmann et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- A Combination Therapy of Donepezil and Cilostazol for Patients With Moderate Alzheimer Disease: Pilot Follow-Up Study
- (2009) Heii Arai et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Phosphodiesterase 5 Inhibition Improves Synaptic Function, Memory, and Amyloid- Load in an Alzheimer's Disease Mouse Model
- (2009) D. Puzzo et al. JOURNAL OF NEUROSCIENCE
- Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia
- (2009) S. M. Grauer et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety
- (2009) Alex B Burgin et al. NATURE BIOTECHNOLOGY
- Phosphodiesterase Inhibitors Enhance Object Memory Independent of Cerebral Blood Flow and Glucose Utilization in Rats
- (2009) Kris Rutten et al. NEUROPSYCHOPHARMACOLOGY
- Phosphodiesterase genes and antidepressant treatment response: A review
- (2008) Karin Esposito et al. ANNALS OF MEDICINE
- The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging
- (2008) K. Domek-Łopacińska et al. BRAIN RESEARCH
- Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia
- (2008) C. J. Schmidt et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents
- (2008) F. Josef van der Staay et al. NEUROPHARMACOLOGY
- A placebo-controlled study of sildenafil effects on cognition in schizophrenia
- (2008) Donald C. Goff et al. PSYCHOPHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started